StreetInsider.com News Articles

Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships

Wed, 10 Jun 2026 14:13:00 -0400

LYON, France--(BUSINESS WIRE)-- Regulatory News:

Poxel (Euronext: POXEL - FR0012432516), a biopharmaceutical company listed on Euronext Paris, announces the appointment of Yves Decadt as Chief Executive Officer with effect from 10 June 2026. He succeeds Nicolas Trouche, whose role was specifically designed to support Poxel during the restructuring period that began in August 2025, with the aim of successfully developing and implementing the Continuation Plan. This transition, previously agreed to take place during the first half of 2026, is proceeding according to schedule. The Board of Directors expresses its deep gratitude to Nicolas Trouche for the exemplary commitment

Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships

Wed, 10 Jun 2026 14:13:00 -0400

LYON, France--(BUSINESS WIRE)-- Regulatory News:

Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships

Wed, 10 Jun 2026 14:13:00 -0400

LYON, France--(BUSINESS WIRE)-- Regulatory News:

Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships

Wed, 10 Jun 2026 14:13:00 -0400

LYON, France--(BUSINESS WIRE)-- Regulatory News:

Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships

Wed, 10 Jun 2026 14:13:00 -0400

LYON, France--(BUSINESS WIRE)-- Regulatory News:

Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships

Wed, 10 Jun 2026 14:13:00 -0400

LYON, France--(BUSINESS WIRE)-- Regulatory News:

Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships

Wed, 10 Jun 2026 14:13:00 -0400

LYON, France--(BUSINESS WIRE)-- Regulatory News:

Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships

Wed, 10 Jun 2026 14:13:00 -0400

LYON, France--(BUSINESS WIRE)-- Regulatory News:

Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships

Wed, 10 Jun 2026 14:13:00 -0400

LYON, France--(BUSINESS WIRE)-- Regulatory News:

Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships

Wed, 10 Jun 2026 14:13:00 -0400

LYON, France--(BUSINESS WIRE)-- Regulatory News:

Poxel Reports First Quarter 2026 Revenue and Provides a Business Update

Wed, 20 May 2026 02:00:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the first quarter of 2026 reached JPY 2.3 billion (€12.8 million 1), up 36% compared to the first quarter of 2025.
Poxel generated revenue of €1.277 million for the first quarter of 2026.
Consolidated net sales of TWYMEEG® in Japan for Sumitomo Pharma2 reached JPY 9.35 billion (€51 million), up 40% compared to the previous fiscal year.
During Sumitomo Pharma’s fiscal year 20253, Poxel received royalties of 10% on TWYMEEG® net sales
Sumitomo Pharma expects moderate double-digit growth slightly above 10% in TWYMEEG® sales for its fiscal year 20264.
Sumitomo Pharma notably expects TWYMEEG® net sales

Poxel Reports First Quarter 2026 Revenue and Provides a Business Update

Wed, 20 May 2026 02:00:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the first quarter of 2026 reached JPY 2.3 billion (€12.8 million 1), up 36% compared to the first quarter of 2025.

Poxel generated revenue of €1.277 million for the first quarter of 2026.

Consolidated net sales of TWYMEEG® in Japan for Sumitomo Pharma2 reached JPY 9.35 billion (€51 million), up 40% compared to the previous fiscal year.

During Sumitomo Pharma’s fiscal year 20253, Poxel received royalties of 10% on TWYMEEG® net sales

Sumitomo Pharma expects moderate double-digit growth slightly above 10% in TWYMEEG® sales for its fiscal year 20264.

Sumitomo Pharma notably expects TWYMEEG® net sales

Poxel Reports First Quarter 2026 Revenue and Provides a Business Update

Wed, 20 May 2026 02:00:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the first quarter of 2026 reached JPY 2.3 billion (€12.8 million 1), up 36% compared to the first quarter of 2025.

Poxel generated revenue of €1.277 million for the first quarter of 2026.

Consolidated net sales of TWYMEEG® in Japan for Sumitomo Pharma2 reached JPY 9.35 billion (€51 million), up 40% compared to the previous fiscal year.

During Sumitomo Pharma’s fiscal year 20253, Poxel received royalties of 10% on TWYMEEG® net sales

Sumitomo Pharma expects moderate double-digit growth slightly above 10% in TWYMEEG® sales for its fiscal year 20264.

Sumitomo Pharma notably expects TWYMEEG® net sales

Poxel Reports First Quarter 2026 Revenue and Provides a Business Update

Wed, 20 May 2026 02:00:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the first quarter of 2026 reached JPY 2.3 billion (€12.8 million 1), up 36% compared to the first quarter of 2025.

Poxel generated revenue of €1.277 million for the first quarter of 2026.

Consolidated net sales of TWYMEEG® in Japan for Sumitomo Pharma2 reached JPY 9.35 billion (€51 million), up 40% compared to the previous fiscal year.

During Sumitomo Pharma’s fiscal year 20253, Poxel received royalties of 10% on TWYMEEG® net sales

Sumitomo Pharma expects moderate double-digit growth slightly above 10% in TWYMEEG® sales for its fiscal year 20264.

Sumitomo Pharma notably expects TWYMEEG® net sales

Poxel Reports First Quarter 2026 Revenue and Provides a Business Update

Wed, 20 May 2026 02:00:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the first quarter of 2026 reached JPY 2.3 billion (€12.8 million 1), up 36% compared to the first quarter of 2025.

Poxel generated revenue of €1.277 million for the first quarter of 2026.

Consolidated net sales of TWYMEEG® in Japan for Sumitomo Pharma2 reached JPY 9.35 billion (€51 million), up 40% compared to the previous fiscal year.

During Sumitomo Pharma’s fiscal year 20253, Poxel received royalties of 10% on TWYMEEG® net sales

Sumitomo Pharma expects moderate double-digit growth slightly above 10% in TWYMEEG® sales for its fiscal year 20264.

Sumitomo Pharma notably expects TWYMEEG® net sales

Poxel Reports First Quarter 2026 Revenue and Provides a Business Update

Wed, 20 May 2026 02:00:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the first quarter of 2026 reached JPY 2.3 billion (€12.8 million 1), up 36% compared to the first quarter of 2025.

Poxel generated revenue of €1.277 million for the first quarter of 2026.

Consolidated net sales of TWYMEEG® in Japan for Sumitomo Pharma2 reached JPY 9.35 billion (€51 million), up 40% compared to the previous fiscal year.

During Sumitomo Pharma’s fiscal year 20253, Poxel received royalties of 10% on TWYMEEG® net sales

Sumitomo Pharma expects moderate double-digit growth slightly above 10% in TWYMEEG® sales for its fiscal year 20264.

Sumitomo Pharma notably expects TWYMEEG® net sales

Poxel Reports First Quarter 2026 Revenue and Provides a Business Update

Wed, 20 May 2026 02:00:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the first quarter of 2026 reached JPY 2.3 billion (€12.8 million 1), up 36% compared to the first quarter of 2025.

Poxel generated revenue of €1.277 million for the first quarter of 2026.

Consolidated net sales of TWYMEEG® in Japan for Sumitomo Pharma2 reached JPY 9.35 billion (€51 million), up 40% compared to the previous fiscal year.

During Sumitomo Pharma’s fiscal year 20253, Poxel received royalties of 10% on TWYMEEG® net sales

Sumitomo Pharma expects moderate double-digit growth slightly above 10% in TWYMEEG® sales for its fiscal year 20264.

Sumitomo Pharma notably expects TWYMEEG® net sales

Poxel Reports First Quarter 2026 Revenue and Provides a Business Update

Wed, 20 May 2026 02:00:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the first quarter of 2026 reached JPY 2.3 billion (€12.8 million 1), up 36% compared to the first quarter of 2025.

Poxel generated revenue of €1.277 million for the first quarter of 2026.

Consolidated net sales of TWYMEEG® in Japan for Sumitomo Pharma2 reached JPY 9.35 billion (€51 million), up 40% compared to the previous fiscal year.

During Sumitomo Pharma’s fiscal year 20253, Poxel received royalties of 10% on TWYMEEG® net sales

Sumitomo Pharma expects moderate double-digit growth slightly above 10% in TWYMEEG® sales for its fiscal year 20264.

Sumitomo Pharma notably expects TWYMEEG® net sales

Poxel Reports First Quarter 2026 Revenue and Provides a Business Update

Wed, 20 May 2026 02:00:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the first quarter of 2026 reached JPY 2.3 billion (€12.8 million 1), up 36% compared to the first quarter of 2025.

Poxel generated revenue of €1.277 million for the first quarter of 2026.

Consolidated net sales of TWYMEEG® in Japan for Sumitomo Pharma2 reached JPY 9.35 billion (€51 million), up 40% compared to the previous fiscal year.

During Sumitomo Pharma’s fiscal year 20253, Poxel received royalties of 10% on TWYMEEG® net sales

Sumitomo Pharma expects moderate double-digit growth slightly above 10% in TWYMEEG® sales for its fiscal year 20264.

Sumitomo Pharma notably expects TWYMEEG® net sales

Poxel Reports First Quarter 2026 Revenue and Provides a Business Update

Wed, 20 May 2026 02:00:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the first quarter of 2026 reached JPY 2.3 billion (€12.8 million 1), up 36% compared to the first quarter of 2025.

Poxel generated revenue of €1.277 million for the first quarter of 2026.

Consolidated net sales of TWYMEEG® in Japan for Sumitomo Pharma2 reached JPY 9.35 billion (€51 million), up 40% compared to the previous fiscal year.

During Sumitomo Pharma’s fiscal year 20253, Poxel received royalties of 10% on TWYMEEG® net sales

Sumitomo Pharma expects moderate double-digit growth slightly above 10% in TWYMEEG® sales for its fiscal year 20264.

Sumitomo Pharma notably expects TWYMEEG® net sales

Poxel Reports First Quarter 2026 Revenue and Provides a Business Update

Wed, 20 May 2026 02:00:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the first quarter of 2026 reached JPY 2.3 billion (€12.8 million 1), up 36% compared to the first quarter of 2025.

Poxel generated revenue of €1.277 million for the first quarter of 2026.

Consolidated net sales of TWYMEEG® in Japan for Sumitomo Pharma2 reached JPY 9.35 billion (€51 million), up 40% compared to the previous fiscal year.

During Sumitomo Pharma’s fiscal year 20253, Poxel received royalties of 10% on TWYMEEG® net sales

Sumitomo Pharma expects moderate double-digit growth slightly above 10% in TWYMEEG® sales for its fiscal year 20264.

Sumitomo Pharma notably expects TWYMEEG® net sales

Poxel Reports First Quarter 2026 Revenue and Provides a Business Update

Wed, 20 May 2026 02:00:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the first quarter of 2026 reached JPY 2.3 billion (€12.8 million 1), up 36% compared to the first quarter of 2025.

Poxel generated revenue of €1.277 million for the first quarter of 2026.

Consolidated net sales of TWYMEEG® in Japan for Sumitomo Pharma2 reached JPY 9.35 billion (€51 million), up 40% compared to the previous fiscal year.

During Sumitomo Pharma’s fiscal year 20253, Poxel received royalties of 10% on TWYMEEG® net sales

Sumitomo Pharma expects moderate double-digit growth slightly above 10% in TWYMEEG® sales for its fiscal year 20264.

Sumitomo Pharma notably expects TWYMEEG® net sales

Poxel Reports First Quarter 2026 Revenue and Provides a Business Update

Wed, 20 May 2026 02:00:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the first quarter of 2026 reached JPY 2.3 billion (€12.8 million 1), up 36% compared to the first quarter of 2025.

Poxel generated revenue of €1.277 million for the first quarter of 2026.

Consolidated net sales of TWYMEEG® in Japan for Sumitomo Pharma2 reached JPY 9.35 billion (€51 million), up 40% compared to the previous fiscal year.

During Sumitomo Pharma’s fiscal year 20253, Poxel received royalties of 10% on TWYMEEG® net sales

Sumitomo Pharma expects moderate double-digit growth slightly above 10% in TWYMEEG® sales for its fiscal year 20264.

Sumitomo Pharma notably expects TWYMEEG® net sales

Poxel Reports First Quarter 2026 Revenue and Provides a Business Update

Wed, 20 May 2026 02:00:00 -0400

Consolidated net sales of TWYMEEG® in Japan for the first quarter of 2026 reached JPY 2.3 billion (€12.8 million 1), up 36% compared to the first quarter of 2025.

Poxel generated revenue of €1.277 million for the first quarter of 2026.

Consolidated net sales of TWYMEEG® in Japan for Sumitomo Pharma2 reached JPY 9.35 billion (€51 million), up 40% compared to the previous fiscal year.

During Sumitomo Pharma’s fiscal year 20253, Poxel received royalties of 10% on TWYMEEG® net sales

Sumitomo Pharma expects moderate double-digit growth slightly above 10% in TWYMEEG® sales for its fiscal year 20264.

Sumitomo Pharma notably expects TWYMEEG® net sales

Poxel: Postponement of the Publication of the 2025 Annual Financial Statements and the Annual Financial Report

Thu, 30 Apr 2026 11:45:00 -0400

LYON, France--(BUSINESS WIRE)-- Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company that leverages its expertise to develop innovative treatments for metabolic diseases, including certain rare diseases (the “Company”), announces the postponement of the publication of its annual financial statements for the fiscal year ended December 31, 2025, and its 2025 annual financial report.
This decision is related to the completion, since the Lyon Commercial Court approved the continuation plan on January 22, 2026, of several significant transactions whose accounting treatment requires additional time to finalize the annual report, namely:

the establishment of an equity financing facility